Quince Therapeutics stock maintains Market Outperform rating at JMP on eDSP validation
PositiveFinancial Markets

Quince Therapeutics has received a Market Outperform rating from JMP, following the validation of its eDSP technology. This endorsement highlights the company's potential for growth and innovation in the biotech sector, making it an attractive option for investors. The validation of eDSP is significant as it could lead to advancements in treatment options, further solidifying Quince's position in the market.
— Curated by the World Pulse Now AI Editorial System